Invitrogen™ Human EGF Recombinant Protein

Descripción

Epidermal Growth Factor Recombinant Protein, RP-10927, from Invitrogen.

EGF (Epidermal growth factor) exerts its actions by binding to the EGF Receptor, a 170 kDa protein kinase. Activation of EGFR initiates diverse cellular pathways in response to toxic environmental stimuli, or to EGF binding to the receptor, the EGFR forms homo- or heterodimers with other family members. Each dimeric receptor complex initiates a distinct signaling pathway by recruiting different Src homology 2 (SH2) containing effector proteins. EGF is far and wide expressed in kidney, cerebrum, prostrate and salivary glands. EGF acts as a potent mitogenic factor and the phosphorylated receptor recruits adapter proteins like GRB2 that activates complex downstream signaling cascades. EGF activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STAT modules. Research studies suggest the protein may also play important role in activating the NF-kappa-B signaling cascade. Defects in the EGGF gene are the cause of hypomagnesemia type 4 and dysregulation has been associated with the growth and progression of certain cancers. This is a recombinant protein suitable for use as a control in ELISA and Western blot applications. This protein is reported to have the additional biological activity: ED50 as determined by the dose-dependent proliferation of mouse 3T3 cells <0.1ng/ml. Lyophilized product is stable at room temperature for 3 weeks. Store lyophilized product desiccated at -20°C. Upon reconstitution, store at 4°C for 2-7 days or aliquot and store at -20°C. For long-term storage add either HSA or BSAQ to 0.1%. Avoid repeated freeze-thaw cycles. Reconstitute using distilled water to a concentration not less than 100 ug/ml.